Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.Moderna now expects 2025 revenue to come in between$1.5 billion and $2.5 billion, most of which will come in the second half of the year. The majority of those sales will come from Moderna's Covid shot and newly launched vaccine for respiratory syncytial virus, according to a release.The guidance is down from a prior ...